Cellcutix names Barry Schechter to board
This article was originally published in Scrip
Executive Summary
Cellceutix, a clinical-stage biopharmaceutical company developing therapies in oncology, dermatology and antibiotic applications, has appointed Dr Barry Schechter to its board of directors – effective 1 October 2014. Dr Schecter is the director and a principal of the Department of Cornea and External Disease at Florida Eye Microsurgical Institute. He specializes in ocular pathology and diseases, including infections.